FIELD: pharmaceuticals.
SUBSTANCE: claimed group of inventions relates to pharmaceutical composition intended to provide a means for enhancing the resistance of a mammalian organism to supercooling. Pharmaceutical composition includes a beta-blocker propranolol, sympatholitic reserpine, an antianginal drug ivabradine, an antihistamine drug diphenhydramine, serotonin hydrochloride, neuroleptic agent with hypothermic effect of pericyazine, antithyroid agent propitsil, magnesium sulfate and pharmaceutically acceptable solvent. Agent further comprises a carrier, a lipo-lipid fat emulsion, which may be saturated with an inert gas, such as xenon.
EFFECT: invention provides use of a new agent in emergency medicine.
8 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS INCLUDING FAT EMULSION (VARIANTS), ITS USE AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2668374C1 |
| USE OF XENON IMMOBILIZED IN CARRIER IN AGENT FOR INCREASING BODY RESISTANCE TO HYPOXIA | 2018 |
|
RU2696100C1 |
| AGENT COMPRISING A PERFLUOROCARBON EMULSION (OPTIONS), ITS APPLICATION AND METHOD FOR IMPROVING RESISTANCE OF MAMMAL ORGANISM TO SUPERCOOLING | 2017 |
|
RU2665964C1 |
| MEANS INCLUDING PERFLUORIDECARBON EMULSION (VARIANTS), ITS USE AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2669398C1 |
| METHOD OF INHIBITING TUMOUR GROWTH IN MAMMAL | 2018 |
|
RU2713153C1 |
| AGENT INCLUDING CYCLIC GLUCOSE OLIGOMER (OPTIONS), ITS APPLICATION AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2669399C1 |
| AGENT, ITS USE AND METHOD OF CREATING REVERSIBLE PHARMACOLOGICALLY INDUCED HYPOMETABOLISM AND HYPOTHERMIA | 2017 |
|
RU2669400C1 |
| AGENT, ITS APPLICATION AND METHOD FOR IMPROVING RESISTANCE OF MAMMAL ORGANISM TO SUPERCOOLING | 2017 |
|
RU2665963C1 |
| NOVEL ISOPULEGOL-BASED AGENTS INDUCING HYPOTHERMIA IN ANIMALS | 2023 |
|
RU2814731C1 |
| ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
